News FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Market Closed - Canadian Securities Exchange Other stock markets 03:59:02 2024-05-03 pm EDT			5-day change	1st Jan Change
0.52 ^CAD	+1.96%		-21.21%	-56.67%

Apr. 30	FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	CI
Apr. 25	FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FSD Pharma Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd in an Induced State of Alcohol Intoxication	May. 01	AQ
FSD Pharma : Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd™ in an Induced State of Alcohol Intoxication - Form 6-K	Apr. 30	PU
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	Apr. 30	CI
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd	Apr. 26	AQ
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	Apr. 25	MT
FSD Pharma Provides another Update on Celly Nu's Anticipated Launch of unbuzzd	Apr. 23	AQ
FSD Pharma : Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Form 6-K	Apr. 17	PU
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption	Apr. 16	AQ
FSD Pharma Receives Nasdaq Non-Compliance Notice	Apr. 08	MT
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	Apr. 07	NE
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
FSD Pharma Signs the Agreement With iNGENu CRO to Conduct a Clinical Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adults	Mar. 28	AQ
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	Mar. 27	MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	Mar. 27	MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	Mar. 11	MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	Mar. 11	CI
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 at Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	Mar. 06	AQ
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	Mar. 05	MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Summary

Filters